Biotech stock markets have declined significantly in 2019. This is the result of the most recent capital market report of BIOCOM that was published in October.
Thanks to two major financings for Qiagen and Biontech, 2018 will go down in history as a record year: German biotechnology companies were able to raise more than EUR1.3bn (+95%) from investors for their business development last year. In 2017, the figure was only EUR673m.
Vienna, 27.11.2018 – The 4th Vienna Life Science Report shows that the life science community in Vienna is growing at a steady pace. Once again, BIOCOM carried out the data collection and prepared the report.